APN 1125

Drug Profile

APN 1125

Alternative Names: APN1125

Latest Information Update: 18 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CoMentis
  • Developer Alpharmagen; CoMentis
  • Class Antipsychotics
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Schizophrenia

Most Recent Events

  • 11 Jul 2016 CoMentis and Alpharmagen suspend a phase Ib/IIa trial for Schizophrenia (Treatment-experienced) in USA (PO) (NCT02724917)
  • 01 Apr 2016 Phase-I/II clinical trials in Schizophrenia in USA (PO) (NCT02724917)
  • 30 Mar 2016 CoMentis and Alpharmagen plan a phase Ib/IIa trial for Schizophrenia (Treatment-experienced) in USA (PO) (NCT02724917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top